Literature DB >> 22421222

Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses.

Akiko Maehara1, Ecaterina Cristea, Gary S Mintz, Alexandra J Lansky, Ovidiu Dressler, Sinan Biro, Barry Templin, Renu Virmani, Bernard de Bruyne, Patrick W Serruys, Gregg W Stone.   

Abstract

OBJECTIVES: In a prospective study of the natural history of coronary atherosclerosis using angiography and grayscale and radiofrequency intravascular ultrasound (IVUS)-virtual histology (VH), larger plaque burden, smaller luminal area, and plaque composition thin-cap fibroatheroma emerged as independent predictors of future adverse cardiovascular events.
BACKGROUND: The methodology for IVUS-VH classification for an in vivo natural history study and the prospective image mapping by angiography and grayscale and IVUS-VH have not been established.
METHODS: All culprit and nonculprit lesions (defined as ≥ 30% angiographic visual diameter stenoses) were analyzed. Three epicardial vessels as well as all ≥ 1.5-mm-diameter side branches were divided into 29 CASS (Coronary Artery Surgery Study) segments. Each CASS segment was then subdivided into 1.5-mm-long subsegments, and dimensions were analyzed. All grayscale and IVUS-VH slices from the proximal 6 to 8 cm of the 3 coronary arteries were analyzed, with lesions defined as having more than 3 consecutive slices with ≥ 40% plaque burden categorized as: 1) VH thin-cap fibroatheroma; 2) thick-cap fibroatheroma; 3) pathological intimal thickening; 4) fibrotic plaque; or 5) fibrocalcific plaque. The locations of angiographic and grayscale and IVUS-VH lesions were recorded in relation to the corresponding coronary artery ostium and nearby side branches.
RESULTS: The 3-year cumulative rate of major adverse cardiovascular events was 20.4%. Events were adjudicated to culprit lesions in 12.9% of patients and to nonculprit lesions in 11.6%. On multivariate analysis, nonculprit lesions associated with recurrent events were characterized by a plaque burden ≥ 70% (hazard ratio: 5.03; 95% confidence interval: 2.51 to 10.11; p < 0.0001), a minimal luminal area ≤ 4.0 mm(2) (hazard ratio: 3.21; 95% confidence interval: 1.61 to 6.42; p = 0.001), and IVUS-VH phenotype of a thin-cap fibroatheroma (hazard ratio: 3.35; 95% confidence interval: 1.77 to 6.36; p < 0.001).
CONCLUSIONS: Three-vessel multimodality coronary artery imaging was feasible and allowed the identification of lesion-level predictors for future events in this natural history study.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22421222     DOI: 10.1016/j.jcmg.2011.11.019

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  13 in total

Review 1.  Heterogeneity of Coronary Plaque Morphology and Natural History: Current Understanding and Clinical Significance.

Authors:  Marina Zaromytidou; Antonios P Antoniadis; Gerasimos Siasos; Ahmet Umit Coskun; Ioannis Andreou; Michail I Papafaklis; Michelle Lucier; Charles L Feldman; Peter H Stone
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 2.  Methods to assess bioresorbable vascular scaffold devices behaviour after implantation.

Authors:  Alberto Pernigotti; Elisabetta Moscarella; Giosafat Spitaleri; Claudia Scardino; Kohki Ishida; Salvatore Brugaletta
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

3.  Comparison of coronary plaque subtypes in male and female patients using 320-row MDCTA.

Authors:  Faisal Khosa; Atif N Khan; Khurram Nasir; Arash Bedayat; Zehra Malik; Ali F Jon; Ahmad R Cheema; Melvin E Clouse; Francine K Welty
Journal:  Atherosclerosis       Date:  2012-12-13       Impact factor: 5.162

Review 4.  Imaging atherosclerosis and risk of plaque rupture.

Authors:  Eric A Osborn; Farouc A Jaffer
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

5.  Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy.

Authors:  Yoshiki Matsuo; Andrew Cassar; Jing Li; Andreas J Flammer; Byoung-Joo Choi; Joerg Herrmann; Rajiv Gulati; Ryan J Lennon; Soo-Jin Kang; Akiko Maehara; Hironori Kitabata; Takashi Akasaka; Lilach O Lerman; Sudhir S Kushwaha; Amir Lerman
Journal:  Eur Heart J       Date:  2013-06-19       Impact factor: 29.983

Review 6.  Advances in Intravascular Imaging: New Insights into the Vulnerable Plaque from Imaging Studies.

Authors:  Taishi Yonetsu; Ik Kyung Jang
Journal:  Korean Circ J       Date:  2017-11-09       Impact factor: 3.243

7.  Relationship between plaque composition by virtual histology intravascular ultrasound and clinical outcomes after percutaneous coronary intervention in saphenous vein graft disease patients: study protocol of a prospective cohort study.

Authors:  Yin Liu; Hai-Bo Wang; Xiang Li; Jian-Yong Xiao; Ji-Xiang Wang; Kathleen H Reilly; Bo Sun; Jing Gao
Journal:  BMC Cardiovasc Disord       Date:  2018-12-12       Impact factor: 2.298

Review 8.  Mechanically Rotating Intravascular Ultrasound (IVUS) Transducer: A Review.

Authors:  Jin-Ho Sung; Jin-Ho Chang
Journal:  Sensors (Basel)       Date:  2021-06-05       Impact factor: 3.576

9.  Circulating Microparticles and Coronary Plaque Components Assessed by Virtual Histology Intravascular Ultrasound of the Target Lesion in Patients with Stable Angina.

Authors:  Pil-Ki Min; Minhee Cho; Sung-Yu Hong; Jong-Youn Kim; Eui-Young Choi; Young-Won Yoon; Byoung Kwon Lee; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

10.  Evolution of nonculprit coronary atherosclerotic plaques assessed by serial virtual histology intravascular ultrasound in patients with ST-segment elevation myocardial infarction and chronic total occlusion.

Authors:  Jeehoon Kang; Ki-Hyun Jeon; Seong-Wook Kim; Jin Joo Park; Chang-Hwan Yoon; Jung-Won Suh; Young-Seok Cho; Tae-Jin Youn; In-Ho Chae; Dong-Ju Choi
Journal:  Coron Artery Dis       Date:  2016-12       Impact factor: 1.439

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.